Who was studied, and how
Five numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 19 other studies
155people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
Efsubaglutide Alfa 1 mg
placebo
Probably lowered long-term blood sugar−0.95
Reported higher fasting blood sugar, no range given+1.59
Reported lower body weight, no range given−0.72
randomisedthe abstract, start to end
At week 24, HbA1c decreased by -1.69% (95% CI -1.91 to -1.47) with Efsubaglutide Alfa 1 mg versus -0.74% (-0.96 to -0.52) with placebo, a placebo-corrected difference of -0.95% (95% CI -1.25 to -0.65; …
… -0.50 mmol/L with placebo (difference - 1.59 mmol/L; p < 0.001).
… not significant (-2.8% vs. -1.3%; LSM -0.72 kg; p = 0.137).
… with placebo (p < 0.0001; odds ratio 8.3).
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Glycemic control
−1.69−1.91 to −1.47
HbA1cEfsubaglutide Alfa 1 mg vs placebo
−0.95−1.25 to −0.65
Fasting plasma glucose (FPG)Efsubaglutide Alfa 1 mg vs placebo
1.59
Body weightEfsubaglutide Alfa 1 mg vs placebo
−0.72
HbA1c <7.0%Efsubaglutide Alfa 1 mg vs placebo
OR 8.3
Investigational compoundsGlycemic controlBody weight & composition
Investigational compounds × glycemic controlhelps?replicated
unlikelylikely
0.780.78 without it
Investigational compounds × body weight & compositionhelps?settled
unlikelylikely
1.001.00 without it
← favours treatmentfavours comparator →
1 / 6